Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report released on Tuesday,Benzinga reports. They currently have a $240.00 price objective on the stock.

Several other equities research analysts also recently commented on KRYS. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Chardan Capital reissued a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. Finally, Citigroup dropped their price objective on Krystal Biotech from $215.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, May 16th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and an average target price of $211.13.

Krystal Biotech Trading Up 0.1%

NASDAQ:KRYS opened at $142.58 on Tuesday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $219.34. The business’s 50-day moving average price is $141.26 and its two-hundred day moving average price is $158.17. The firm has a market capitalization of $4.12 billion, a price-to-earnings ratio of 34.27 and a beta of 0.65.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. Sell-side analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KRYS. Brooklyn Investment Group raised its holdings in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after acquiring an additional 105 shares during the period. Twin Tree Management LP bought a new position in Krystal Biotech during the 1st quarter worth about $29,000. Fifth Third Bancorp raised its stake in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after purchasing an additional 105 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock valued at $58,000 after purchasing an additional 177 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Krystal Biotech in the first quarter valued at about $74,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).